CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients

Karaaslan, Zerrin; Kürtüncü, Murat; Akçay, Halil İbrahim; Gündüz, Tuncay; Altunrende, Burcu; Türkoğlu, Recai; Eraksoy, Mefküre; Ulusoy, Canan; Yılmaz, Vuslat; Tüzün, Erdem

doi:10.1159/000517770

Cited by 4 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum, plasma, CSF CSF, plasma, serum: ↑ MS versus healthy control [191,199] and NIND CSF: ↑ in CIS versus HC [166] CXCL13 CSF: Serum does not correlate with CSF [128,137] CSF: ↑RMS and PMS versus NIND and OIND [122][123][124][125][126][127] CSF: ↑CIS that convert to MS [129][130][131]; ↑ disease activity in RMS [124,[127][128][129] CSF>Serum: ↓ with DMT [127,132,133] Serum: Predict response to fingolimod [134] IL-17A…”

Section: Csf and Serum Inflammatory Mediatorsmentioning

confidence: 99%

“…CXCL13 CSF levels also correlated with current and future disease activity, particularly in RRMS, including relapse rate, disability, and MRI lesions [124, 127, 128]. CSF and serum CXCL3 levels decreased with steroids, with DMT including B‐cell depleting therapy, and in some cases may predict response to therapy [127, 132–134].…”

Section: Emerging Liquid Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Emerging imaging and liquid biomarkers in multiple sclerosis

et al. 2023

View full text Add to dashboard Cite

The advent of highly effective disease modifying therapy has transformed the landscape of multiple sclerosis (MS) care over the last two decades. However, there remains a critical, unmet need for sensitive and specific biomarkers to aid in diagnosis, prognosis, treatment monitoring, and the development of new interventions, particularly for people with progressive disease. This review evaluates the current data for several emerging imaging and liquid biomarkers in people with MS. MRI findings such as the central vein sign and paramagnetic rim lesions may improve MS diagnostic accuracy and evaluation of therapy efficacy in progressive disease. Serum and cerebrospinal fluid levels of several neuroglial proteins, such as neurofilament light chain and glial fibrillary acidic protein, show potential to be sensitive biomarkers of pathologic processes such as neuro‐axonal injury or glial‐inflammation. Additional promising biomarkers, including optical coherence tomography, cytokines and chemokines, microRNAs, and extracellular vesicles/exosomes, are also reviewed, among others. Beyond their potential integration into MS clinical care and interventional trials, several of these biomarkers may be informative of MS pathogenesis and help elucidate novel targets for treatment strategies.

show abstract

Section: Csf and Serum Inflammatory Mediatorsmentioning

confidence: 99%

Section: Emerging Liquid Biomarkersmentioning

confidence: 99%

Emerging imaging and liquid biomarkers in multiple sclerosis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It was also reported that baseline serum CXCL13 level before administration of fingolimod was significantly lower in the group that responded to fingolimod than in the group that did not (mean level of responders vs. nonresponders, 58.25 pg/mL vs. 127.2 pg/mL; p = 0.009). This suggests that serum CXCL13 level indicates treatment response to fingolimod [ 90 ].…”

Section: Main Subjectsmentioning

confidence: 99%

Protein biomarkers in multiple sclerosis

Kim

2023

encephalitis

View full text Add to dashboard Cite

This review aimed to elucidate protein biomarkers in body fluids, such as blood and cerebrospinal fluid (CSF), to identify those that may be used for early diagnosis of multiple sclerosis (MS), prediction of disease activity, and monitoring of treatment response among MS patients. The potential biomarkers elucidated in this review include neurofilament proteins (NFs), glial fibrillary acidic protein (GFAP), leptin, brain-derived neurotrophic factor (BDNF), chitinase-3-like protein 1 (CHI3L1), C-X-C motif chemokine 13 (CXCL13), and osteopontin (OPN), with each biomarker playing a different role in MS. GFAP, leptin, and CHI3L1 levels were increased in MS patient groups compared to the control group. NFs are the most studied proteins in the MS field, and significant correlations with disease activity, future progression, and treatment outcomes are evident. GFAP CSF level shows a different pattern by MS subtype. Increased concentration of CHI3L1 in the blood/CSF of clinically isolated syndrome (CIS) is an independent predictive factor of conversion to definite MS. BDNF may be affected by chronic progression of MS. CHI3L1 has potential as a biomarker for early diagnosis of MS and prediction of disability progression, while CXCL13 has potential as a biomarker of prognosis of CIS and reflects MS disease activity. OPN was an indicator of disease severity. A periodic detailed patient evaluation should be performed for MS patients, and broadly and easily accessible biomarkers with higher sensitivity and specificity in clinical settings should be identified.

show abstract

“…Regarding other MS therapies, CXCL13 has been reported to decrease in patients after treatment with natalizumab or methylprednisolone [ 152 , 169 , 195 , 196 ], mitoxantrone [ 197 ], but not after interferon-beta treatment [ 152 ]. Furthermore, baseline CXCL13 levels were also shown to predict success with fingolimod; nonresponder patients had elevated pretreatment serum levels of CXCL13 compared to patients responsive to fingolimod [ 198 ].…”

Section: Fluid Biomarkers Of Multiple Sclerosismentioning

confidence: 99%

Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations

Biernacki

Kokas

Sandi

et al. 2022

IJMS

View full text Add to dashboard Cite

Introduction: Multiple Sclerosis (MS) is the most common immune-mediated chronic neurodegenerative disease of the central nervous system (CNS) affecting young people. This is due to the permanent disability, cognitive impairment, and the enormous detrimental impact MS can exert on a patient’s health-related quality of life. It is of great importance to recognise it in time and commence adequate treatment at an early stage. The currently used disease-modifying therapies (DMT) aim to reduce disease activity and thus halt disability development, which in current clinical practice are monitored by clinical and imaging parameters but not by biomarkers found in blood and/or the cerebrospinal fluid (CSF). Both clinical and radiological measures routinely used to monitor disease activity lack information on the fundamental pathophysiological features and mechanisms of MS. Furthermore, they lag behind the disease process itself. By the time a clinical relapse becomes evident or a new lesion appears on the MRI scan, potentially irreversible damage has already occurred in the CNS. In recent years, several biomarkers that previously have been linked to other neurological and immunological diseases have received increased attention in MS. Additionally, other novel, potential biomarkers with prognostic and diagnostic properties have been detected in the CSF and blood of MS patients. Areas covered: In this review, we summarise the most up-to-date knowledge and research conducted on the already known and most promising new biomarker candidates found in the CSF and blood of MS patients. Discussion: the current diagnostic criteria of MS relies on three pillars: MRI imaging, clinical events, and the presence of oligoclonal bands in the CSF (which was reinstated into the diagnostic criteria by the most recent revision). Even though the most recent McDonald criteria made the diagnosis of MS faster than the prior iteration, it is still not an infallible diagnostic toolset, especially at the very early stage of the clinically isolated syndrome. Together with the gold standard MRI and clinical measures, ancillary blood and CSF biomarkers may not just improve diagnostic accuracy and speed but very well may become agents to monitor therapeutic efficacy and make even more personalised treatment in MS a reality in the near future. The major disadvantage of these biomarkers in the past has been the need to obtain CSF to measure them. However, the recent advances in extremely sensitive immunoassays made their measurement possible from peripheral blood even when present only in minuscule concentrations. This should mark the beginning of a new biomarker research and utilisation era in MS.

show abstract

CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients

Cited by 4 publications

References 11 publications

Emerging imaging and liquid biomarkers in multiple sclerosis

Emerging imaging and liquid biomarkers in multiple sclerosis

Protein biomarkers in multiple sclerosis

Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations

Contact Info

Product

Resources

About